Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
FRISCO, Texas, Jan. 26, 2016 -- Greatbatch Inc., (NYSE:GB) today announced that a jury in the United States District Court for the District of Delaware returned a verdict finding that AVX Corporation and AVX Filters Corporation infringed two Greatbatch patents, and in the process awarded Greatbatch $37.5 million in damages. The complaint, filed in April 2013, alleged that AVX had infringed Greatbatch patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate its patented technology.
The jury's decision marked an important milestone in Greatbatch’s effort to defend its patented technology. “Greatbatch is committed to challenging willful and deliberate patent infringement and to taking all steps necessary to ensure that our intellectual property is protected,” said Thomas J. Hook, Greatbatch president & CEO. "I want to express my sincere appreciation for the time and careful attention the Court and the jury gave this important case."
During trial, Greatbatch presented evidence that certain AVX products infringed claims of U.S. Patent Nos. 5,905,627 and 5,333,095. In advance of trial, the Court determined that the jury should also include damages for infringement of U.S. Patent No. 6,888,715.
In awarding Greatbatch $37.5 million in damages, the jury also confirmed the validity of Greatbatch’s asserted patents, as well as two other Greatbatch patents that AVX had challenged.
Additional information about the case – Greatbatch Ltd. v. AVX Corporation and AVX Filters Corporation, Civil Action No. 13-cv-723-LPS – can be obtained from publicly available court records. Greatbatch was represented in this case by Harris Beach PLLC.
About Greatbatch, Inc.
Greatbatch, Inc. (NYSE:GB) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopaedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company’s brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available at www.greatbatch.com.
In October 2015, Greatbatch, Inc. completed its acquisition of Lake Region Medical, with the combined company expected to be renamed Integer Holdings Corporation later this year (subject to shareholder approval).
Investor Relations Contact: Anthony Borowicz [email protected] tel 716-759-5809 Media Contact: Christopher Knospe [email protected] tel 716-759-5727
